A deeper understanding of the molecular mechanisms of MYC roles and its interactors in each B-cell lymphoma types provides a wide set of candidates for the development of a better personalized targeted therapy that in near future could lead to successful treatments with less toxicity. Here, MYC is linked to B-cell non-Hodgkin lymphoma.